|
Post by pguererro on Jun 28, 2018 21:24:44 GMT -5
West Lake Village highly qualified additions
|
|
|
Post by centralcoastinvestor on Jun 28, 2018 22:00:08 GMT -5
Sayhay: Metformin is actually $4 a month and is extremely efficacious. I got torched a year ago for saying this because somebody had data about “early use of mealtime insulin” in Type 2 diabetes. That may be great data but 1) we can’t talk about that data and 2) it’s not accepted in the medical algorithm today. I love you guys but you sometimes speak in a language that isn’t real world. I got torched to suggest that Metformin is the greatest drug for Type 2 Diabetes. In today’s Real World Metformin is the greatest drug for the current system we have. $4. In a utopia you could argue that early initiation of meal time insulin saves the organs and especially the pancreas by taking the load off the pancreas and giving the body what it wants. I agree with all of that. Guess what.... not only can we not talk about that....we won’t be able to have that discussion in years. We are talking about the marketability of Afrezza today. Just stop discounting your credibility on Afrezza in the Type 2 market. GLP1’s now with 1 shot a week give you a 2% A1c reduction with limited to no hypo and you lose 10% of your body weight. SGLT2i’s are an oral pill that gives you 1-1.5 A1c drop with a 4% weight loss and zero hypo. Im sure I’ll get tore up from somebody telling ho these drugs pound the pancreas or kidneys and maybe they do. However, both drugs are being prescribed to mega-blockbuster status and patients are benefitting from these drugs. I just ask that everybody be real world with their comments. Of course if we could talk about the Advantages of early meal time insulin therapy to a Type 2 patient with diabetes we would. However, WE CANT. In the meantime Type 2 patients are experiencing therapy results they have never ever experienced before with SGLT2i’s and more importantly new once weekly GLP1’s. The problem with Metformin, GLP1’s, and all of the other non insulin treatments is that it is a death sentence for the pancreas. While the A1c looks just fine with these drugs, the Time In Range (TIR) is still all over the place at meal time and damage is being done to the feet, the eyes and most organs in a diabetic. All of those drugs delay the use of insulin which is what is really needed. CGMs will show the diabetic world that all of these best selling drugs are doing nothing to prevent long term diabetic damage.
|
|
|
Post by akemp3000 on Jun 28, 2018 22:08:39 GMT -5
Sayhay: Metformin is actually $4 a month and is extremely efficacious. I got torched a year ago for saying this because somebody had data about “early use of mealtime insulin” in Type 2 diabetes. That may be great data but 1) we can’t talk about that data and 2) it’s not accepted in the medical algorithm today. I love you guys but you sometimes speak in a language that isn’t real world. I got torched to suggest that Metformin is the greatest drug for Type 2 Diabetes. In today’s Real World Metformin is the greatest drug for the current system we have. $4. In a utopia you could argue that early initiation of meal time insulin saves the organs and especially the pancreas by taking the load off the pancreas and giving the body what it wants. I agree with all of that. Guess what.... not only can we not talk about that....we won’t be able to have that discussion in years. We are talking about the marketability of Afrezza today. Just stop discounting your credibility on Afrezza in the Type 2 market. GLP1’s now with 1 shot a week give you a 2% A1c reduction with limited to no hypo and you lose 10% of your body weight. SGLT2i’s are an oral pill that gives you 1-1.5 A1c drop with a 4% weight loss and zero hypo. Im sure I’ll get tore up from somebody telling ho these drugs pound the pancreas or kidneys and maybe they do. However, both drugs are being prescribed to mega-blockbuster status and patients are benefitting from these drugs. I just ask that everybody be real world with their comments. Of course if we could talk about the Advantages of early meal time insulin therapy to a Type 2 patient with diabetes we would. However, WE CANT. In the meantime Type 2 patients are experiencing therapy results they have never ever experienced before with SGLT2i’s and more importantly new once weekly GLP1’s. The 45 new diabetes drugs that have been approved in the past ten years have not resulted in any significant benefit to the general population of diabetics. I'm going to side with the former Chief Scientific Medical Officer of the American Diabetes Association on this
|
|
|
Post by mango on Jun 28, 2018 22:23:48 GMT -5
Sayhay: Metformin is actually $4 a month and is extremely efficacious. I got torched a year ago for saying this because somebody had data about “early use of mealtime insulin” in Type 2 diabetes. That may be great data but 1) we can’t talk about that data and 2) it’s not accepted in the medical algorithm today. I love you guys but you sometimes speak in a language that isn’t real world. I got torched to suggest that Metformin is the greatest drug for Type 2 Diabetes. In today’s Real World Metformin is the greatest drug for the current system we have. $4. In a utopia you could argue that early initiation of meal time insulin saves the organs and especially the pancreas by taking the load off the pancreas and giving the body what it wants. I agree with all of that. Guess what.... not only can we not talk about that....we won’t be able to have that discussion in years. We are talking about the marketability of Afrezza today. Just stop discounting your credibility on Afrezza in the Type 2 market. GLP1’s now with 1 shot a week give you a 2% A1c reduction with limited to no hypo and you lose 10% of your body weight. SGLT2i’s are an oral pill that gives you 1-1.5 A1c drop with a 4% weight loss and zero hypo. Im sure I’ll get tore up from somebody telling ho these drugs pound the pancreas or kidneys and maybe they do. However, both drugs are being prescribed to mega-blockbuster status and patients are benefitting from these drugs. I just ask that everybody be real world with their comments. Of course if we could talk about the Advantages of early meal time insulin therapy to a Type 2 patient with diabetes we would. However, WE CANT. In the meantime Type 2 patients are experiencing therapy results they have never ever experienced before with SGLT2i’s and more importantly new once weekly GLP1’s. Metformin is an endocrine disruptor
|
|
|
Post by pguererro on Jun 28, 2018 23:00:05 GMT -5
You guys didn’t listen to 1 word I said. I’m talking about discussions we can have with prescribers starting tomorrow and for the next 2 years. I’m glad you are all scientists and almost docs due to what you have read. You are a thousand miles away from what the medical community has to say and as WRONG as they are they put pen to paper or in today’s world check the therapeutic box. Stop with the data can’t cant be presented to prescribers and won’t be available for years. Our best shot is to get Endos to start writing for Type 1’s after the stat trial info. All of your “secret data” can’t be presented and is actually not respected by today’s thought leaders. Hoping Kendall can help with this but again, he’s been meeting with thought leaders for 3 months prior to ADA and the post ADA market response has been crap.
|
|
|
PPS
Jun 28, 2018 23:06:30 GMT -5
Post by pguererro on Jun 28, 2018 23:06:30 GMT -5
Mango: I’m sure your patients are doing fine without using Metformin.
|
|
|
PPS
Jun 28, 2018 23:31:35 GMT -5
via mobile
Post by pguererro on Jun 28, 2018 23:31:35 GMT -5
Central Coast Investor: I launched Victoza. Not only is it not a pancreas killer. There is data to show that GLP1’s maintain the Beya Cell function. And they can actually talk about that!! Stop with the reckless comments. It doesn’t add to your credibility.
|
|
|
Post by peppy on Jun 28, 2018 23:44:22 GMT -5
Sayhay: Metformin is actually $4 a month and is extremely efficacious. I got torched a year ago for saying this because somebody had data about “early use of mealtime insulin” in Type 2 diabetes. That may be great data but 1) we can’t talk about that data and 2) it’s not accepted in the medical algorithm today. I love you guys but you sometimes speak in a language that isn’t real world. I got torched to suggest that Metformin is the greatest drug for Type 2 Diabetes. In today’s Real World Metformin is the greatest drug for the current system we have. $4. In a utopia you could argue that early initiation of meal time insulin saves the organs and especially the pancreas by taking the load off the pancreas and giving the body what it wants. I agree with all of that. Guess what.... not only can we not talk about that....we won’t be able to have that discussion in years. We are talking about the marketability of Afrezza today. Just stop discounting your credibility on Afrezza in the Type 2 market. GLP1’s now with 1 shot a week give you a 2% A1c reduction with limited to no hypo and you lose 10% of your body weight. SGLT2i’s are an oral pill that gives you 1-1.5 A1c drop with a 4% weight loss and zero hypo. Im sure I’ll get tore up from somebody telling ho these drugs pound the pancreas or kidneys and maybe they do. However, both drugs are being prescribed to mega-blockbuster status and patients are benefitting from these drugs. I just ask that everybody be real world with their comments. Of course if we could talk about the Advantages of early meal time insulin therapy to a Type 2 patient with diabetes we would. However, WE CANT. In the meantime Type 2 patients are experiencing therapy results they have never ever experienced before with SGLT2i’s and more importantly new once weekly GLP1’s. ok, on the GLP1's. What is the data on the thyroid cancer? mango can you get me the post marketing list of complications on the GLP1's? Any thyroid cancer showing up? The SGLT2's how stupid can we be. While HbA1c does come down when glucose leaves your body through your bladder, even though the hbA1c comes down, we are ridiculous to believe having glucose leave through our bladder in urine is a good thing. And the commercials, seem almost fraudulent. The Black box warning of amputation on one of them.
|
|
|
Post by centralcoastinvestor on Jun 29, 2018 0:04:11 GMT -5
Central Coast Investor: I launched Victoza. Not only is it not a pancreas killer. There is data to show that GLP1’s maintain the Beya Cell function. And they can actually talk about that!! Stop with the reckless comments. It doesn’t add to your credibility. Victoza causes an overworked pancreas to produce more insulin. I don’t see how this helps the health of Beta Cell production in the pancreas. In fact, it could cause the pancreas to die sooner because it over works an already tired pancreas. Unfortunately most of the non insulin drugs out there for diabetes contort the body into doing things that it is not meant to do in attempt to avoid what is actually needed .... insulin. For instance, how natural is a drug that causes sugar to come out in the urine. What kind of long term affect might that have on the body. I am not trying to reckless with my comments but there are a lot of long term side effects from the non insulin drugs that are not talked about.
|
|
|
Post by pguererro on Jun 29, 2018 0:10:40 GMT -5
Again...love you guys and will continue to come to this site for info.
|
|
|
Post by pguererro on Jun 29, 2018 0:18:56 GMT -5
CCI: I’m going to bed. Glucagon Like Peptide is an enzyme that we all have in our intestines and stomach. To boost GLP 1 is a good thing. It does all types of good shit and does not put stress on the pancreas. I now sound like a moron. I’m sorry. I’m going to bed but seriously u sound dumb
|
|
|
PPS
Jun 29, 2018 0:23:56 GMT -5
via mobile
Post by pguererro on Jun 29, 2018 0:23:56 GMT -5
BTW: Victoza once daily shot delivered a 1.5 A1c drop on an 8.5 Type 2 baseline study. Ozempic (novo new GLP1 delivers same A1c drop with a 12% reduction in body weight.
|
|
|
PPS
Jun 29, 2018 0:28:09 GMT -5
via mobile
dejude42 likes this
Post by pguererro on Jun 29, 2018 0:28:09 GMT -5
No matter what we all debate. The stock price is crap.
|
|
|
Post by dejude42 on Jun 29, 2018 4:58:05 GMT -5
No matter what we all debate. The stock price is crap. Is it a real ASK PPS or nefariously being Creativity manipulated? Short daily trade on NASDAQ and New York were both traded above 60% short? A simple questions," Who is relinquishing these shorted shares and are they churning this type of trade action?" (http://regsho.finra.org/regsho-Index.html 20180628|MNKD|391999|1331|581515|Q 67.41% shorted 20180628|MNKD|64755|0|98685|N 65.62% shorted Short trade was designated to protect the investor from total loss. Short trade used as a platform to receive personal gains especially in small traded companies over and over becomes a pyramid scheme in reverse. Imagine buying an insurance policy, burn down your house and then collect. People go to jail for this: as it would be considered fraud. Creativity Manipulation uses weakness as a strategy in implementation. The only tool to protect is the gathering of data to insure patterns do not exist. Without data Creativity Manipulation causes disastrous results and will always continue, the abusers think of this as a game: not an investment. What do you do? I Play the Market... Have you ever heard that. A proper investment takes work and time. The current spread is very easy to control. 1.) Stack shares on the ASK PPS (blocks ASK PPS rise) 2.) Relinquish or delete shares off current BID 2a.) Open a widen spread. 2b.) Any integer gap / window allows a lower ASK PPS insertion 3.) Market Makers fills 3a.) Relinquished shares in thousandths and ten thousandths of a cent below current ASK PPS. 3b.) 1/10000 of a penny below current ASK PPS is not a current ASK PPS sale. 3c.) Many Last sale charts show these as a rounded up current ASK PPS. Fidelity does a rounded up last sale. The relinquishment of non owned short shares being a cheap tool for devious trading. Short share use is One hell of a back door to lowering ASK PPS. Imagine a group of traders working in unison the power they could obtain. Sec has punished such past actions when discovered. The mission of the SEC is to protect investors; maintain fair, orderly, and efficient markets; and facilitate capital formation. The SEC strives to promote a market environment that is worthy of the public's trust. www.sec.gov/about.shtml The problem MNKD currently has is being a small daily traded company, the strength is not there for self protection. The SEC is working on changes to help. In this day and age AI monitors exist an Algorithmic programs need to react immediate on the data.
|
|
|
Post by liane on Jun 29, 2018 5:22:38 GMT -5
You guys are straying far and wide. Locking the thread.
|
|